CPhA Statement on Health Canada Approval of MifeGymiso
The Canadian Pharmacists Association (CPhA) welcomes Health Canada’s approval of MifeGymiso (mifepristone and misoprostol tablets) for the medical termination of pregnancy, ensuring women have access to this medication in Canada. The availability of MifeGymiso will improve the capacity of the health care system to provide medical abortions.
However, CPhA is disappointed that access will be limited at this initial stage through distribution only at clinics through physician dispensing, despite the key role community pharmacists play in the distribution and patient care associated with medications. We believe that potential risks associated with the dispensing of this medication can be mitigated through proper training and processes in place for both physicians and pharmacists.
Access to abortion services in Canada is often an issue, with geography a substantial barrier, particularly in rural or remote communities. Pharmacists can play a key role in the distribution and patient care associated with this medication to ensure it is provided in a safe, convenient and timely manner. Including community pharmacists in the dispensing and counseling for medical abortion, in collaboration with the prescribing physician, enhances the care that a woman receives, improves access and follow-up.
Canadian pharmacists are the medication experts on the health care team and provide high-quality accessible care in each community across the country, ensuring Canadians have timely access to the medications and care they require. Pharmacists routinely provide care in the area of reproductive health, notably in responding to the needs of women requiring emergency contraception.
CPhA is collaborating with the Society of Obstetricians and Gynaecologists of Canada (SOGC) to develop mandatory training programs and clinical practice guidelines for physicians and pharmacists to ensure Canadians have safe access to this medication.
July 30, 2015